Join us to learn about plans for the RPGRIP1 Gene Therapy Program in 2022. Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of these benchmarks and what it means for the program. We'll also discuss the plans...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
“We are very excited to have Tainsen join the Odylia Advisory Board,” said Scott Dorfman, Odylia Therapeutics’ CEO....
Odylia and Foundation Fighting Blindness are hosting a 4-part preclinical and translational research webinar series. The series will focus on genetic technologies and will provide advice and educational materials to researchers in the rare disease space. If you are currently working in or thinking about preclinical...
Converting vertical information approaches into horizontal solutions for all members of the rare disease community....
Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships....